Liquidia Corp.
http://www.liquidia.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Liquidia Corp.
Sandoz And Liquidia Triumph On Treprostinil
Sandoz and partner Liquidia have welcomed a US court decision which found that interference by United Therapeutics with the launch of their generic treprostinil injection rival to Remodulin caused the pair losses of more than $137m.
Life After Chevron: US Supreme Court Ruling Cited In FDA Exclusivity Decision Challenges
Disputes over orphan and new clinical investigation exclusivity are among the early drug and biologic cases where legal filings cite the Loper Bright decision, which overturned the Chevron doctrine of deference to agency actions.
Deal Watch: Takeda Calls Upon The UK’s F-star Again For Bispecific Candidates
Plus deals involving Sanofi/Adocia, Sirnaomics/EDIRNA, Eisai/DRI Healthcare, Sangamo/Voyager, Liquidia/Pharmosa, Tonix/Upsher-Smith and more.
Keeping Track: US FDA Approves Heron’s Zynrelef In Post-Op Pain; Amgen/AZ Submit Tezepelumab For Severe Asthma
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Controlled Release
- Pulmonary
-
Biotechnology
- Drug Discovery Tools
- Nanotechnology, Chips, etc.
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
-
- Liquidia Technologies, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice